As of 2025-12-29, the Relative Valuation of Myriad Genetics Inc (MYGN) is (77.77) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.48 USD, the upside of Myriad Genetics Inc based on Relative Valuation is -1300.2%.
The range of the Relative Valuation is (77.26) - (77.26) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.3x - 18.0x | 17.9x |
| Forward P/E multiples | 18.0x - 18.7x | 18.3x |
| Fair Price | (77.26) - (77.26) | (77.77) |
| Upside | -1292.2% - -1292.2% | -1300.2% |
| Date | P/E |
| 2025-12-26 | -1.51 |
| 2025-12-24 | -1.52 |
| 2025-12-23 | -1.53 |
| 2025-12-22 | -1.57 |
| 2025-12-19 | -1.52 |
| 2025-12-18 | -1.56 |
| 2025-12-17 | -1.62 |
| 2025-12-16 | -1.60 |
| 2025-12-15 | -1.63 |
| 2025-12-12 | -1.68 |
| 2025-12-11 | -1.70 |
| 2025-12-10 | -1.68 |
| 2025-12-09 | -1.71 |
| 2025-12-08 | -1.65 |
| 2025-12-05 | -1.65 |
| 2025-12-04 | -1.71 |
| 2025-12-03 | -1.71 |
| 2025-12-02 | -1.63 |
| 2025-12-01 | -1.64 |
| 2025-11-28 | -1.78 |
| 2025-11-26 | -1.77 |
| 2025-11-25 | -1.84 |
| 2025-11-24 | -1.80 |
| 2025-11-21 | -1.72 |
| 2025-11-20 | -1.61 |
| 2025-11-19 | -1.50 |
| 2025-11-18 | -1.54 |
| 2025-11-17 | -1.55 |
| 2025-11-14 | -1.56 |
| 2025-11-13 | -1.48 |
| 2025-11-12 | -1.52 |
| 2025-11-11 | -1.55 |
| 2025-11-10 | -1.51 |
| 2025-11-07 | -1.47 |
| 2025-11-06 | -1.47 |
| 2025-11-05 | -1.53 |
| 2025-11-04 | -1.50 |
| 2025-11-03 | -1.90 |
| 2025-10-31 | -1.87 |
| 2025-10-30 | -1.85 |
| 2025-10-29 | -1.84 |
| 2025-10-28 | -1.89 |
| 2025-10-27 | -1.89 |
| 2025-10-24 | -1.90 |
| 2025-10-23 | -1.87 |
| 2025-10-22 | -1.83 |
| 2025-10-21 | -1.88 |
| 2025-10-20 | -1.84 |
| 2025-10-17 | -1.82 |
| 2025-10-16 | -1.88 |